1. Home
  2. NOAH vs IRWD Comparison

NOAH vs IRWD Comparison

Compare NOAH & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NOAH

Noah Holdings Limited

HOLD

Current Price

$8.45

Market Cap

653.4M

Sector

Finance

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$4.26

Market Cap

658.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOAH
IRWD
Founded
2005
1998
Country
China
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
653.4M
658.5M
IPO Year
2010
2009

Fundamental Metrics

Financial Performance
Metric
NOAH
IRWD
Price
$8.45
$4.26
Analyst Decision
Hold
Buy
Analyst Count
2
3
Target Price
$11.00
$7.67
AVG Volume (30 Days)
86.8K
2.0M
Earning Date
05-27-2026
05-11-2026
Dividend Yield
5.66%
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.24
Revenue
N/A
$298,276,000.00
Revenue This Year
N/A
$57.95
Revenue Next Year
$5.71
$4.39
P/E Ratio
$13.29
$15.50
Revenue Growth
N/A
8.88
52 Week Low
$8.40
$0.72
52 Week High
$12.84
$5.78

Technical Indicators

Market Signals
Indicator
NOAH
IRWD
Relative Strength Index (RSI) 25.71 53.60
Support Level N/A $3.80
Resistance Level $10.73 $4.88
Average True Range (ATR) 0.19 0.19
MACD -0.01 -0.03
Stochastic Oscillator 1.47 73.96

Price Performance

Historical Comparison
NOAH
IRWD

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: